Elucidating the genomic and transcriptomic landscape of L858R vs ex19del EGFR-mutated NSCLC

• Published in: Journal of clinical oncology Vol. 41; no. 16_suppl; p. 8530
• Main Authors: Pang, Mengyuan, Yeo, Jia Chi, Alvarez, Jacob, Sim, Ngak Leng, Ng, Win Pin, Lai, Gillianne, Tan, Aaron C., Jain, Amit, Tan, Wan Ling, Kanesvaran, Ravindran, Ng, Quan Sing, Lim, Darren Wan-Teck, Ang, Mei-Kim, Lim, Tony Kiat Hon, Ong, Boon-Hean, Chua, Kevin Lee Min, Tan, Daniel Shao-Weng, Skanderup, Anders
• Format: Journal Article
• Language: English
• Published: American Society of Clinical Oncology 01.06.2023

8530Background: Epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) is heterogeneous and L858R derive less benefit from osimertinib than ex19del in both the metastatic and adjuvant setting, which remains poorly understood. We sought to examine the genomic and transcrip...